Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.

Teglicar did not affect this parameter although a slight trend toward reduction was seen ( Fig. 5 ).

also in 4,078 other papers

Teglicar reduced basal insulin levels; a nonsignificant trend toward a reduction of basal blood glucose was also observed, whereas EGP, glucose infusion rate (GIR), and peripheral insulin sensitivity (GU), assessed with a hyperinsulinemic-euglycemic clamp, did not differ between treated animals and controls.

also in 5,406 other papers